BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and enzymatic activity of highly selective human mitochondrial thymidine kinase inhibitors. 2001

S Manfredini, and P G Baraldi, and E Durini, and L Porcu, and A Angusti, and S Vertuani, and N Solaroli, and E De Clercq, and A Karlsson, and J Balzarini
Dipartimento di Scienze Farmaceutiche, Università di Ferrara, Italy. mv9@dns.unfie.it

Highly selective arabinofuranosyl nucleosides, which inhibit the mitochondrial thymidine kinase (TK-2) without affecting the closely related herpes simplex virus type 1 thymidine kinase (HSV-1 TK), varicella-zoster virus thymidine kinase (VZV-TK), cytosolic thymidine kinase (TK-1) or the multifunctional Drosophila melanogaster deoxyribonucleoside kinase (Dm-dNK), have been obtained. SAR studies indicate a close relation between the length of the substituent at the 2' position of the arabinofuranosyl moiety and the inhibitory activity.

UI MeSH Term Description Entries
D008928 Mitochondria Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Each mitochondrion is surrounded by a double limiting membrane. The inner membrane is highly invaginated, and its projections are called cristae. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP. They contain distinctive RIBOSOMES, transfer RNAs (RNA, TRANSFER); AMINO ACYL T RNA SYNTHETASES; and elongation and termination factors. Mitochondria depend upon genes within the nucleus of the cells in which they reside for many essential messenger RNAs (RNA, MESSENGER). Mitochondria are believed to have arisen from aerobic bacteria that established a symbiotic relationship with primitive protoeukaryotes. (King & Stansfield, A Dictionary of Genetics, 4th ed) Mitochondrial Contraction,Mitochondrion,Contraction, Mitochondrial,Contractions, Mitochondrial,Mitochondrial Contractions
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001087 Arabinonucleosides Nucleosides containing arabinose as their sugar moiety. Arabinofuranosylnucleosides
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013937 Thymidine Kinase An enzyme that catalyzes the conversion of ATP and thymidine to ADP and thymidine 5'-phosphate. Deoxyuridine can also act as an acceptor and dGTP as a donor. (From Enzyme Nomenclature, 1992) EC 2.7.1.21. Deoxythymidine Kinase,Deoxypyrimidine Kinase,Kinase, Deoxypyrimidine,Kinase, Deoxythymidine,Kinase, Thymidine
D014764 Viral Proteins Proteins found in any species of virus. Gene Products, Viral,Viral Gene Products,Viral Gene Proteins,Viral Protein,Protein, Viral,Proteins, Viral
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D020128 Inhibitory Concentration 50 The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. IC50,Concentration 50, Inhibitory

Related Publications

S Manfredini, and P G Baraldi, and E Durini, and L Porcu, and A Angusti, and S Vertuani, and N Solaroli, and E De Clercq, and A Karlsson, and J Balzarini
Novel selective human mitochondrial kinase inhibitors: design, synthesis and enzymatic activity.
April 2007, Bioorganic & medicinal chemistry,
S Manfredini, and P G Baraldi, and E Durini, and L Porcu, and A Angusti, and S Vertuani, and N Solaroli, and E De Clercq, and A Karlsson, and J Balzarini
Mitochondrial thymidine kinase inhibitors.
January 2005, Current topics in medicinal chemistry,
S Manfredini, and P G Baraldi, and E Durini, and L Porcu, and A Angusti, and S Vertuani, and N Solaroli, and E De Clercq, and A Karlsson, and J Balzarini
The design, synthesis and properties of highly potent and selective inhibitors of herpes simplex virus types 1 and 2 thymidine kinase.
January 1998, Antiviral chemistry & chemotherapy,
S Manfredini, and P G Baraldi, and E Durini, and L Porcu, and A Angusti, and S Vertuani, and N Solaroli, and E De Clercq, and A Karlsson, and J Balzarini
Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors.
January 2012, Bioorganic & medicinal chemistry,
S Manfredini, and P G Baraldi, and E Durini, and L Porcu, and A Angusti, and S Vertuani, and N Solaroli, and E De Clercq, and A Karlsson, and J Balzarini
Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors.
January 2022, Journal of medicinal chemistry,
S Manfredini, and P G Baraldi, and E Durini, and L Porcu, and A Angusti, and S Vertuani, and N Solaroli, and E De Clercq, and A Karlsson, and J Balzarini
Design, synthesis and enzymatic evaluation of 6-bridged imidazolyluracil derivatives as inhibitors of human thymidine phosphorylase.
April 2007, The Journal of pharmacy and pharmacology,
S Manfredini, and P G Baraldi, and E Durini, and L Porcu, and A Angusti, and S Vertuani, and N Solaroli, and E De Clercq, and A Karlsson, and J Balzarini
Rational design of highly selective spleen tyrosine kinase inhibitors.
December 2012, Journal of medicinal chemistry,
S Manfredini, and P G Baraldi, and E Durini, and L Porcu, and A Angusti, and S Vertuani, and N Solaroli, and E De Clercq, and A Karlsson, and J Balzarini
Mitochondrial thymidine kinase and the enzymatic network regulating thymidine triphosphate pools in cultured human cells.
November 2007, The Journal of biological chemistry,
S Manfredini, and P G Baraldi, and E Durini, and L Porcu, and A Angusti, and S Vertuani, and N Solaroli, and E De Clercq, and A Karlsson, and J Balzarini
Highly selective azadipeptide nitrile inhibitors for cathepsin K: design, synthesis and activity assays.
February 2013, Organic & biomolecular chemistry,
S Manfredini, and P G Baraldi, and E Durini, and L Porcu, and A Angusti, and S Vertuani, and N Solaroli, and E De Clercq, and A Karlsson, and J Balzarini
Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.
May 2013, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!